The four main objectives of the Pepfidomics, RIA and Proteomics (PRP) Core are to: 1) train CURE: DDRCC investigators in the use of peptide, radioimmunoassay and proteomic techniques for their own research activities; 2) perform services for CURE: DDRCC investigators for studies requiring expensive equipment or requiring too much skill to be performed in individual laboratories (i.e. mass spectral analysis, microsequence analysis, amino acid analysis, etc.); 3) provide instrumentation for studies requiring expensive equipment and simple protocols where CURE: DDRCC investigators and staff can be trained to perform experiments (i.e. radioimmunoassay of large numbers of samples, HPLC studies using the same method repeatedly); 4) provide unique reagents necessary for CURE: DDRCC investigators to conduct their own research (i.e. radiolabels, synthetic peptides, fluorescent labeled synthetic peptides). Many physiological, pharmacological, and biochemical studies performed at CURE: DDRCC utilize peptide reagents, including biologically active agonists and antagonists, cell permeable mimics of intracellular proteins that interfere with signal transduction steps, enzyme substrates, etc. Proper care and evaluation of these reagents are necessary for valid results. CURE: DDRCC investigators are trained in how to make, store and evaluate stock solutions, how to dilute peptides properly, and how to evaluate the loss or modification of peptides under experimental conditions. The PRP will also provide services and equipment for CURE: DDRCC investigators to acquire state of the art characterization of peptides. A wealth of antibodies has been produced by the Antibody Core during the past funding period, and these continue to be an integral component of several studies performed at CURE: DDRCC. These antibodies will be tested and distributed bythe PRP Core. The personnel of the Core will continue to enable investigators to perform radioimmunoassay and ELISA techniques. The Shared Proteomics Facility is a new addition to the CURE: DDRCC. Purification and characterization of proteins by high performance capillary electrophoresis, high performance liquid chromatography, microsequence analysis, and mass spectral analysis require instrumentation far too costly for individual laboratories and expertise to perform complicated techniques properly and efficiently. Many of the chromatography techniques used for years by Dr. Reeve and his staff (1) are directly applicable to proteomics. This is especially true for low abundance proteins of a cell because 2D gels are limited in volume of sample that can be applied. Liquid chromatography also offers the ability to perform 3D or 4D separations so proteins can be highly purified, resulting in cleaner subsequent mass spectral patterns. The PRP will train CURE: DDRCC investigators in proteomic techniques, perform liquid chromatography, mass spectral analysis and informatics necessary to characterize the proteomes under investigation. The Proteomic facilities include a variety of high performance mass spectrometers capable of providing detailed information on the structure of biomolecules, such as time-of-flight, magnetic sector, quadrupole, triple quadrupole, quadrupole ion trap and quadrupole-time-of-flight (QTOF) tandem mass spectrometers (i.e., MS/MS). These instruments are equipped with conventional electron impact (EI), chemical (CI), atmospheric pressure chemical (APCI) and fast atom bombardment (FAB) ion sources, in addition to electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI) sources for the sensitive analysis of peptides and proteins. On-line separation methods such as capillary HPLC are interfaced to ESI-MS systems to characterize low abundance level peptide and protein samples. The Resource also has access to supporting systems for proteomics research, including gel electrophoresis, automated protein digesters, and a robotic MALDI sample spotter. A computer server network used for high speed protein sequence database searching is dedicated for mass spectrometry-based protein identification.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK041301-16
Application #
6863980
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (M1))
Project Start
2004-12-01
Project End
2009-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
16
Fiscal Year
2005
Total Cost
$53,881
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Osadchiy, Vadim; Labus, Jennifer S; Gupta, Arpana et al. (2018) Correlation of tryptophan metabolites with connectivity of extended central reward network in healthy subjects. PLoS One 13:e0201772
May, Folasade P; Yu, Christine; Kaunitz, Jonathan (2018) High quality of cancer care in the Department of Veterans Affairs (VA). Am J Cancer Res 8:761-762
Freise, Amanda C; Zettlitz, Kirstin A; Salazar, Felix B et al. (2018) Immuno-PET in Inflammatory Bowel Disease: Imaging CD4-Positive T Cells in a Murine Model of Colitis. J Nucl Med 59:980-985
Nih, Lina R; Gojgini, Shiva; Carmichael, S Thomas et al. (2018) Dual-function injectable angiogenic biomaterial for the repair of brain tissue following stroke. Nat Mater 17:642-651
Severino, Amie; Chen, Wenling; Hakimian, Joshua K et al. (2018) Mu-opioid receptors in nociceptive afferents produce a sustained suppression of hyperalgesia in chronic pain. Pain 159:1607-1620
Mirshafiee, Vahid; Sun, Bingbing; Chang, Chong Hyun et al. (2018) Toxicological Profiling of Metal Oxide Nanoparticles in Liver Context Reveals Pyroptosis in Kupffer Cells and Macrophages versus Apoptosis in Hepatocytes. ACS Nano 12:3836-3852
Ali, Ayub; Ng, Hwee L; Blankson, Joel N et al. (2018) Highly Attenuated Infection With a Vpr-Deleted Molecular Clone of Human Immunodeficiency Virus-1. J Infect Dis 218:1447-1452
Pothoulakis, Charalabos; Torre-Rojas, Monica; Duran-Padilla, Marco A et al. (2018) CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis. Int J Cancer 142:334-346
Martin, Clair R; Osadchiy, Vadim; Kalani, Amir et al. (2018) The Brain-Gut-Microbiome Axis. Cell Mol Gastroenterol Hepatol 6:133-148
Olson, Christine A; Vuong, Helen E; Yano, Jessica M et al. (2018) The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. Cell 173:1728-1741.e13

Showing the most recent 10 out of 1097 publications